Hedia to Showcase Improvements in Glycaemic Control of T1D users at ATTD

Hedia to Showcase Improvements in Glycaemic Control of T1D users at ATTD

Hedia, which is developing digital therapeutics for insulin-requiring diabetes, is announcing its participation in the scientific program of Advanced Technologies & Treatments for Diabetes (ATTD). At the conference, Hedia will present the retrospective study which investigated if type 1 diabetes (T1D) users of the Hedia Diabetes Assistant (HDA) can achieve clinically relevant improvements in glycaemic control after 12 weeks use.

Positive Impact of Digital Health Solutions

The real-world study was conducted among engaged users of HDA and shows positive outcomes in terms of glycaemic control: a significant lowering of estimated HbA1c (eA1c) and an increased estimated time-in-range (eTIR) over the course of 12 weeks.

‘’Hedia is honoured to be among the experts speaking at ATTD to shed light on the innovation of technologies and treatments for diabetes in order to make a positive change in the lives of people with insulin dependence’’, says CEO Peter Lucas.

‘’Findings from this study reveal the positive impact of digital health solutions in type 1 diabetes management in terms of significantly improving glycaemic control’’, says CSO, MD, PhD, MPA Henrik Gudbergsen.

About Hedia and ATTD

About Hedia ApS: Hedia is a company based in Copenhagen, Denmark that develops and markets digital therapeutics for insulin-requiring diabetes. The first generation of the product is integrated with blood glucose meters and is on the market in the EU.

Based on habits of the individual person with diabetes and personalised input, Hedia generates insulin recommendations by taking all aspects of diabetes management into account – such as recording blood glucose readings, keeping track of active insulin, and measuring carbs. The digital therapeutics improves care for insulin-requiring diabetes. For more information, visit hedia.co.

About ATTD: The annual Advanced Technologies & Treatments for Diabetes meetings are a premier international forum for clinicians and scientists to present and discuss state-of-the-art advancements in diabetes care and technology. For more information, visit attd.kenes.com.

More articles